$SBFM (COVID-19) Meet Dr. Steve Slilaty Professo
Post# of 212
(Total Views: 599)
Posted On: 07/22/2020 5:05:54 PM
$SBFM (COVID-19) Meet Dr. Steve Slilaty
Professor, Doctor, CEO, Visionary
Dr. Slilaty is an accomplished scientist and a highly skilled business executive.
He received his Bachelor of Science degree in Genetics and Biochemistry from Cornell University and his Ph.D. in Molecular Biology & Biochemistry from the University of Arizona.
Dr. Slilaty is a leader in the bioscience industry and is referenced in editorials, reviews and textbooks.
His extensive contributions to science included the discovery of a new class of enzymes (IUBMB Enzyme: EC 3.4.21.88) and the development of key technology for the Human Genome Project (TrueBlue Cloning System).
With a passion for medicine, he founded three biotech companies and took one public. The company he took public, Genomics One Corporation reached $1 billion market cap.
At Sunshine Biopharma Dr. Slilaty is working with the same determination as he pioneers a path towards the discovery of ground breaking drugs for the treatment of aggressive forms of cancer.
What is Adva-27a?
Our Flagship AntiCancer Drug
https://www.sunshinebiopharma.com/
Dr. Steve N. Slilaty, Ph.D. serves as a Chairman of the Board, President, Chief Executive Officer of Sunshine Biopharma, Inc., since October 15, 2009.
In addition, since February 2002, Dr. Slilaty has been President and Chief Scientific Officer of Advanomics Corporation, Montreal, Canada, a privately held company engaged in the research, development and commercialization of drugs for the treatment of various forms of cancer. Advanomics Corporation is the third in a line of biotechnology companies that Dr. Slilaty founded and managed through their early and mid-stages of development.
The first, Quantum Biotechnologies Inc. later known as Qbiogene Inc., was founded in 1991 and grew to over $60 million in annual sales. Today, Qbiogene is a member of a family of companies owned by MP Biomedicals, one of the international suppliers of biotechnology reagents with a catalogue containing over 55,000 products.
The second company which Dr. Slilaty founded, Genomics One Corporation, now known as Alert B&C Corporation, conducted an initial public offering (IPO) of its capital stock in 1999 and, on the basis of its ownership of
Dr. Slilaty’s patented TrueBlue® Technology, Genomics One became one of the handful of participants in the Human Genome Project. Formerly a research team leader of the Biotechnology Research Institute, a division of the National Research Council of Canada, Dr. Slilaty also served as a consultant in a management and advisory capacity for a Canadian biotechnology company between 1995 and 1997 during which time the company completed one of the biotechnology IPO‘s in Canada raising over $34 million.
Dr. Slilaty received his Ph.D degree from the University of Arizona in 1983 and a Bachelor of Science degree from Cornell University in 1976.
Adva-27a, Our Flagship Anticancer Drug
https://sunshinebiopharma.com/drugs-development.html
Generic Drugs - Coming Soon
SBI-Anastrozole for treatment of Breast Cancer
SBI-Letrozole for treatment of Breast Cancer
SBI-Bicalutamide treatment of Prostate Cancer
SBI-Finasteride for treatment of BPH (Benign Prostatic Hyperplasia)
https://sunshinebiopharma.com/drugs-market.html
Professor, Doctor, CEO, Visionary
Dr. Slilaty is an accomplished scientist and a highly skilled business executive.
He received his Bachelor of Science degree in Genetics and Biochemistry from Cornell University and his Ph.D. in Molecular Biology & Biochemistry from the University of Arizona.
Dr. Slilaty is a leader in the bioscience industry and is referenced in editorials, reviews and textbooks.
His extensive contributions to science included the discovery of a new class of enzymes (IUBMB Enzyme: EC 3.4.21.88) and the development of key technology for the Human Genome Project (TrueBlue Cloning System).
With a passion for medicine, he founded three biotech companies and took one public. The company he took public, Genomics One Corporation reached $1 billion market cap.
At Sunshine Biopharma Dr. Slilaty is working with the same determination as he pioneers a path towards the discovery of ground breaking drugs for the treatment of aggressive forms of cancer.
What is Adva-27a?
Our Flagship AntiCancer Drug
https://www.sunshinebiopharma.com/
Dr. Steve N. Slilaty, Ph.D. serves as a Chairman of the Board, President, Chief Executive Officer of Sunshine Biopharma, Inc., since October 15, 2009.
In addition, since February 2002, Dr. Slilaty has been President and Chief Scientific Officer of Advanomics Corporation, Montreal, Canada, a privately held company engaged in the research, development and commercialization of drugs for the treatment of various forms of cancer. Advanomics Corporation is the third in a line of biotechnology companies that Dr. Slilaty founded and managed through their early and mid-stages of development.
The first, Quantum Biotechnologies Inc. later known as Qbiogene Inc., was founded in 1991 and grew to over $60 million in annual sales. Today, Qbiogene is a member of a family of companies owned by MP Biomedicals, one of the international suppliers of biotechnology reagents with a catalogue containing over 55,000 products.
The second company which Dr. Slilaty founded, Genomics One Corporation, now known as Alert B&C Corporation, conducted an initial public offering (IPO) of its capital stock in 1999 and, on the basis of its ownership of
Dr. Slilaty’s patented TrueBlue® Technology, Genomics One became one of the handful of participants in the Human Genome Project. Formerly a research team leader of the Biotechnology Research Institute, a division of the National Research Council of Canada, Dr. Slilaty also served as a consultant in a management and advisory capacity for a Canadian biotechnology company between 1995 and 1997 during which time the company completed one of the biotechnology IPO‘s in Canada raising over $34 million.
Dr. Slilaty received his Ph.D degree from the University of Arizona in 1983 and a Bachelor of Science degree from Cornell University in 1976.
Adva-27a, Our Flagship Anticancer Drug
https://sunshinebiopharma.com/drugs-development.html
Generic Drugs - Coming Soon
SBI-Anastrozole for treatment of Breast Cancer
SBI-Letrozole for treatment of Breast Cancer
SBI-Bicalutamide treatment of Prostate Cancer
SBI-Finasteride for treatment of BPH (Benign Prostatic Hyperplasia)
https://sunshinebiopharma.com/drugs-market.html
(0)
(0)Sunshine Biopharma Inc. (SBFM) Stock Research Links
$MJ